...
首页> 外文期刊>Thorax: The Journal of the British Thoracic Society >Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment.
【24h】

Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment.

机译:哮喘患者气道上皮中可诱导型一氧化氮合酶和环加氧酶-2的表达增加,并通过糖皮质激素治疗对其进行调节。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Nitric oxide (NO) and prostanoids are mediators of vascular and bronchial tone that are postulated to be involved in asthma. Increased levels of both are found in asthmatic subjects and are synthesised by enzymes that have cytokine inducible forms: inducible NO synthase (iNOS) and cyclo-oxygenase-2 (COX-2), respectively. We hypothesised that the in vivo expression of iNOS and COX-2 in the airways would be increased in asthma, and that these cytokine inducible enzymes may represent targets for regulation by corticosteroid treatment. METHODS: Bronchial biopsy specimens were obtained from three groups of subjects: atopic asthmatics treated with beta(2) agonists alone (n=7), atopic asthmatics additionally receiving regular treatment with corticosteroids (n=8), and non-asthmatic control subjects (n=10). Expression of iNOS and COX-2 mRNA and immunoreactive protein was studied using in situ hybridisation and quantitative immunohistochemistry. RESULTS: Immunoreactivity and the hybridisation signal for iNOS and COX-2 were mainly localised in the airway epithelium. The proportion of epithelium immunostained was significantly greater in the non-steroid treated asthmatic subjects (iNOS 8.6 (1.8)%; COX-2 26.3 (4.6)%) than either the steroid treated asthmatics (iNOS 3.4 (1.0)%, p=0.009; COX-2 13.0 (0.6)%, p=0.0015) or the non-asthmatic controls (iNOS 4.2 (0.9)%, p=0.018; COX-2 11.6 (0.6)%, p=0.0003). Similarly, the hybridisation signal was stronger in the non-steroid treated group of asthmatic subjects than in the other two groups. CONCLUSIONS: These findings highlight the potential role of the airway epithelium both as a contributor to the inflammatory process in asthma and as a target for inhaled corticosteroid treatment in this disease.
机译:背景:一氧化氮(NO)和前列腺素是血管和支气管张力的介质,被认为与哮喘有关。两者均在哮喘患者中升高,并由具有细胞因子诱导形式的酶合成:分别是诱导型NO合酶(iNOS)和环加氧酶2(COX-2)。我们假设哮喘中气道中iNOS和COX-2的体内表达会增加,而这些细胞因子诱导酶可能代表皮质类固醇激素治疗的靶标。方法:从三组受试者中获得支气管活检标本:单独使用β(2)激动剂治疗的特应性哮喘(n = 7),另外接受皮质类固醇常规治疗的特应性哮喘(n = 8)和非哮喘性对照受试者(n = 8)。 n = 10)。使用原位杂交和定量免疫组织化学研究了iNOS和COX-2 mRNA和免疫反应蛋白的表达。结果:iNOS和COX-2的免疫反应性和杂交信号主要位于气道上皮。在非类固醇治疗的哮喘患者中,免疫染色的上皮比例显着更高(iNOS 8.6(1.8)%; COX-2 26.3(4.6)%),比任何类固醇治疗的哮喘患者(iNOS 3.4(1.0)%,p = 0.009) ; COX-2 13.0(0.6)%,p = 0.0015)或非哮喘控制组(iNOS 4.2(0.9)%,p = 0.018; COX-2 11.6(0.6)%,p = 0.0003)。同样,非类固醇治疗哮喘组的杂交信号要强于其他两组。结论:这些发现突出了气道上皮在哮喘炎症过程中的潜在作用以及在该疾病中吸入糖皮质激素治疗的靶标的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号